Thursday, November 07, 2024 12:19:47 AM
You are living a dark speculative fantasy.
I’ve been here many years, and when asked many years ago where an artisan novel autologous biologic such as this might be best developed and launched, I said the UK, for several reasons. It may have been even before I started posting here. Long before Brexit or anyone suggested the FDA may or may not be supportive.
Years ago, people were still scared this technology would cause a massive autoimmune reaction and quickly kill the patient. All large pharma, as the early patents will educate you, missed this technology because they were frightened of potential liability or daunted by the long process toward developing mass production for an autologous therapy.
Still other large pharmaceutical simply didn’t want to go toward a path that might one day lead to a complete cure — given the right development and combinations.
(Note: Iova and Adap do not utilize the same technology.)
I’ve been here many years, and when asked many years ago where an artisan novel autologous biologic such as this might be best developed and launched, I said the UK, for several reasons. It may have been even before I started posting here. Long before Brexit or anyone suggested the FDA may or may not be supportive.
Years ago, people were still scared this technology would cause a massive autoimmune reaction and quickly kill the patient. All large pharma, as the early patents will educate you, missed this technology because they were frightened of potential liability or daunted by the long process toward developing mass production for an autologous therapy.
Still other large pharmaceutical simply didn’t want to go toward a path that might one day lead to a complete cure — given the right development and combinations.
(Note: Iova and Adap do not utilize the same technology.)
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
